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S288 Poster Session IIT cell depletion (TCD) has successfully reduced the risk of graft ver-
sus host disease (GVHD) but concerns about relapse and infections
have limited its application.
Methods: Between 7/2001 and 12/2005, 35 pts underwent TCD
HSCTs as treatment for hematologic malignancies using HLA-
matched (HLA-M)(20 pairs) or mismatched (-MM)(15 pairs) unre-
lated donors. The conditioning regimen, hyperfractionated total
body irradiation (1375 cGy), fludarabine (25 mg/m2) x 5d, and thio-
tepa (5 mg/kg) and antithymocyte globulin 2d, was designed to re-
duce toxicity, while preserving immunosuppression for engraftment.
Donors were $8 of 10 HLA matched by DNA SSOP analyses. Pts
received TCD-peripheral blood stem cells (PBSC) (n5 29) or
TCD-bonemarrow (BM) (n5 6). PBSCs were CD34+ selected (Iso-
lex 300i columns) and BMs agglutinated by soybean lectin, after
which both underwent sheep erythrocyte-rosette sedimentation.
The median age was 40.5yrs (18-63). Diseases included AML (stan-
dard or high risk) and ALL (high risk) CR1, AMLCR2, ALL$CR2,
acute biphenotypic leukemia, CML-CP,MDS, T-PLL.Median fol-
lowup is 52 mos (37-83).
Results: All evaluable pts engrafted neutrophils, and 31/34 evalu-
able pts engrafted platelets. The 100d non-relapse mortality was
20% with infection causing .50% of deaths. 9% developed only
acute GVHD grade II-III and 29% chronic GVHD, with no signif-
icant difference between HLA-M and -MM subsets. Estimated 4 yr
DFS and OS is 56% and 59%, with DFS of 75% for pts with stan-
dard risk and 41% for high risk disease. Two high risk disease pts
relapsed at 31 and 38 mos. Infectious deaths were: 2 viral, 1 toxo-
plasma, 1 fungal, 2 bacterial. Median time to achieve normal
CD3 +CD8+ and CD3 +CD4+ counts were approximately 4-6
and 6-9 mos posttransplantation, respectively. Only 4 pts, who
had been treated with steroids, had CD3 +CD4+ counts \100
cells/ul by 1 yr. 50% of patients reached a normal PHA proliferative
response in vitro within 1 yr.
Conclusions: Outcomes with this cytoreductive regimen followed
by TCD PBSC or BM are similar to those reported for TCD
matched related donor, and for unmodified transplants but with
a much lower incidence of GVHD. Relapse rates, with followup of
.3 yrs, remain remarkably low.351
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The incidence of liver related morbidity and mortality after al-
logeneic hematopoietic cell transplantation (Allo-HCT) in patients
positive for hepatitis B surface antigen (HBsAg +) may increase,
but it has been not well analysed. The aim of this study is to de-
termine the frequency of HBV reactivation and to evaluate the ef-
fect of HBV reactivation on early transplant-related complications
in a retrospective single center cohort. We detected HbsAg+ 23
patients (3.8%) who underwent allo-HCT (n5 680) within 10
years. Median age was 33 years. Twenty-two were male and one
female. Liver function tests were normal and HBV-DNA negative
in 20 patients prior to the transplant. Myeloablative (n5 20) or
fludarabine based-reduced intensity conditioning regimen (n5 3)
were used. Lamivudin prophylaxis was initiated 100 mg p.o o.d.
in 14 patients with conditioning regimen and was continued until
6-12 months after the cessation of immunosuppresion at post-
transplant period. Six patients had HBsAg+ donor, 5 seropositive
(antiHBs with antiHBc IgG, 3 antiHBs alone and 6 were negative
HBV naive. We could not obtain enough data about HBV serol-
ogy of 3 donors. HBV reactivation was observed in 7 patients after
median 4.5 months (range, 0.87-23.5) after the Allo-HCT. All the
patients with HBV reactivation had received myeloablative condi-
tioning. There was an increase of serum ALT (2.5UNL- 54
UNL) level with positivity for HBV-DNA during reactivation.
The reactivation was observed only in one patient during lamivu-
dine prophylaxis 7.6% vs 60%. p5 0.012) while one patient expe-
rienced a reactivation in 2 months after cessation of prophylaxis.Two patients with HBV reactivation had donors positive for
HBsAg. Lamivudin treatment was given in 5 patients after reacti-
vation. Lamivudin resistance was observed in two patients, who re-
ceived second line antiviral treatment. One of those patients died
of fulminant hepatic failure. The incidences of acute or chronic
liver graft versus host disease were not affected from HBV reacti-
vation. The reactivation HBV is one of the most undesired com-
plications of chemo/immunosuppressive treatment in HBsAg
positive Allo-HCT recipients. The prophylaxis with lamivudine
could decrease the frequency of HBV reactivation. But the devel-
opment of the lamivudine resistance is another problem in some
patients requiring long-term treatment. In conclusion, our study
has shown that HBsAg+ recipients did not have a strict limitation
for allo-HCT.352
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Haematopoietic stem cell transplantation (HSCT) is an estab-
lished treatment for various hematological disorders. The moni-
toring of post-transplant engraftment has become a routine
diagnostic assay in the clinical laboratory. PCR-based methodolo-
gies utilizing STR analysis and commercial multiplex assays are
frequently used. However, these commercial kits were originally
formulated for forensic applications and do not completely fulfill
the needs of diagnostic chimerism testing, especially for non-mye-
loablative bone marrow transplants, in which treatment depends
on the status of lineage-specific chimerism. We utilize the Beck-
man-Coulter GenomeLab Human STR Primer Set (Fullerton,
CA) in our clinical laboratory. This kit consists of twelve STR
markers in a single multiplex PCR reaction and has proven highly
informative, sensitive and rapid in routine clinical testing. For use
with this kit, DNA is extracted from peripheral blood, bone mar-
row, and/or CD3/CD33/CD56-enriched fractions sorted on the
BD Biosciences FACSAria Cell Sorting System (San Jose, CA)
and extracted with the Qiagen Blood Kit or Qiagen Micro Kit
(Valencia, CA). 60 blood samples from multiple College of Amer-
ican Pathologists (CAP) proficiency panels were evaluated. These
panels are challenges proctored by CAP and participated in by
up to 80 US labs 3 times per year. Correlation of results were ex-
cellent (r25 0.99). This method has been in use by our laboratory
since the summer of 2005 with approximately 4500 patient sample
studies. In our experience no pre-transplant/donor combination
has yielded a non-informative result, even between siblings. We
have found the STR-based method to be a rapid, specific, sensi-
tive, and cost-effective diagnostic assay for monitoring donor
cell engraftment after HSCT transplantation, making it a respon-
sive tool for rapid clinical decision making. The assay is stream-
lined to provide rapid turn-around-time and requires a minute
amount of DNA making it an excellent tool for patients with
low white blood cell counts. This methodology is also suitable
for detection of maternal cell contamination and for verifying pa-
thology specimen identification.353
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The St. Louis Cord Blood Bank (SLCBB) serves to collect,
process, cryopreserve, and distribute umbilical cord blood for hu-
man transplantation. To date, nearly 1,600 units have been dis-
tributed globally for the treatment of more than 70 diseases
